Showing results (131-140 of 159) with videos related to
Sort By:
Pageof 16
Plos One|October 11, 2019
A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expressionEmilie A Chapeau, Emeline Mandon, Jason Gill, et al.Journal of the American College of Cardiology|March 22, 2008
Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgroundsKengo F Kusano, Makiko Taniyama, Kazufumi Nakamura, et al.Molecular Cancer Therapeutics|August 20, 2021
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor CellsDaisuke Okajima, Satoru Yasuda, Takanori Maejima, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2019
A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient InternalizationYuuri Hashimoto, Kumiko Koyama, Yasuki Kamai, et al.Elife|May 13, 2015
A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097Sébastien Jeay, Swann Gaulis, Stéphane Ferretti, et al.Proceedings of the National Academy of Sciences of the United States of America|March 8, 2017
Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse modelEmilie A Chapeau, Agnieszka Gembarska, Eric Y Durand, et al.Circulation Journal : Official Journal of the Japanese Circulation Society|November 5, 2010
SCN5A mutation is associated with early and frequent recurrence of ventricular fibrillation in patients with Brugada syndromeNobuhiro Nishii, Masahiro Ogawa, Hiroshi Morita, et al.Cancer Discovery|January 10, 2015
JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic responseMaria Kleppe, Minsuk Kwak, Priya Koppikar, et al.Molecular Cancer Therapeutics|June 2, 2012
Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrationsSaskia M Brachmann, Julia Kleylein-Sohn, Swann Gaulis, et al.Journal of Thrombosis and Thrombolysis|April 8, 2019
Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillationKaoru Okishige, Yasuteru Yamauchi, Yuichi Hanaki, et al.Pageof 16